Works matching IS 21938210 AND DT 2022 AND VI 12 AND IP 1
Results: 21
Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 203, doi. 10.1007/s13555-021-00658-x
- By:
- Publication type:
- Article
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 9, doi. 10.1007/s13555-021-00657-y
- By:
- Publication type:
- Article
Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 233, doi. 10.1007/s13555-021-00654-1
- By:
- Publication type:
- Article
Microneedling and Its Use in Hair Loss Disorders: A Systematic Review.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 41, doi. 10.1007/s13555-021-00653-2
- By:
- Publication type:
- Article
Clinical Utility of Silk-Elastin Sponge in Patients with Chronic and Acute Skin Ulcers: Study Protocol of a Multicenter Clinical Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 243, doi. 10.1007/s13555-021-00651-4
- By:
- Publication type:
- Article
Arthritis Interception in Patients with Psoriasis Treated with Guselkumab.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 5, doi. 10.1007/s13555-021-00650-5
- By:
- Publication type:
- Article
Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 149, doi. 10.1007/s13555-021-00648-z
- By:
- Publication type:
- Article
Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 167, doi. 10.1007/s13555-021-00647-0
- By:
- Publication type:
- Article
Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 185, doi. 10.1007/s13555-021-00646-1
- By:
- Publication type:
- Article
Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 121, doi. 10.1007/s13555-021-00645-2
- By:
- Publication type:
- Article
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 195, doi. 10.1007/s13555-021-00643-4
- By:
- Publication type:
- Article
Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 253, doi. 10.1007/s13555-021-00642-5
- By:
- Publication type:
- Article
Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted Literature Review.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 15, doi. 10.1007/s13555-021-00641-6
- By:
- Publication type:
- Article
Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 137, doi. 10.1007/s13555-021-00640-7
- By:
- Publication type:
- Article
Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 223, doi. 10.1007/s13555-021-00638-1
- By:
- Publication type:
- Article
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 97, doi. 10.1007/s13555-021-00637-2
- By:
- Publication type:
- Article
Re-Evaluating Limitations in Atopic Dermatitis Meta-Analysis Is Important in Interpreting its Results: Limitations of Atopic Dermatitis meta-analysis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 1, doi. 10.1007/s13555-021-00636-3
- By:
- Publication type:
- Article
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 61, doi. 10.1007/s13555-021-00635-4
- By:
- Publication type:
- Article
Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 81, doi. 10.1007/s13555-021-00628-3
- By:
- Publication type:
- Article
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 29, doi. 10.1007/s13555-021-00624-7
- By:
- Publication type:
- Article